These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 26989119)

  • 41. Combined Use of Mesenchymal Stromal Cell Sheet Transplantation and Local Injection of SDF-1 for Bone Repair in a Rat Nonunion Model.
    Chen G; Fang T; Qi Y; Yin X; Di T; Feng G; Lei Z; Zhang Y; Huang Z
    Cell Transplant; 2016 Oct; 25(10):1801-1817. PubMed ID: 26883892
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism.
    Recio-Boiles A; Veeravelli S; Vondrak J; Babiker HM; Scott AJ; Shroff RT; Patel H; Elquza E; McBride A
    World J Gastrointest Oncol; 2019 Oct; 11(10):866-876. PubMed ID: 31662825
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
    Ferreira T; Huber SC; de Moraes Martinelli B; Junior AL; Menezes FH; Orsi FA; Bittar LF; de Oliveira LFG; Sodre LR; Mello TT; Rielli G; Colella MP; de Paula EV; Yamaguti-Hayakawa GG; Montalvão S; Annichino-Bizzacchi JM
    Vascul Pharmacol; 2020 Jan; 124():106608. PubMed ID: 31678199
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
    Yan X; Gu X; Xu Z; Lin H; Wu B
    Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Results of rotational thromboelastometry, coagulation activation markers and thrombin generation assays in orthopedic patients during thromboprophylaxis with rivaroxaban and enoxaparin: a prospective cohort study.
    Oswald E; Velik-Salchner C; Innerhofer P; Tauber H; Auckenthaler T; Ulmer H; Streif W
    Blood Coagul Fibrinolysis; 2015 Mar; 26(2):136-44. PubMed ID: 25396759
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative efficacy and safety of anticoagulants for prevention of venous thromboembolism after hip and knee arthroplasty.
    Hur M; Park SK; Koo CH; Jung ED; Kang P; Kim WH; Kim JT; Jung CW; Bahk JH
    Acta Orthop; 2017 Dec; 88(6):634-641. PubMed ID: 28787226
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
    Gómez Arrayas I; Suárez Fernández C; Gómez Cerezo JF; Betegón Nicolás L; de Salas-Cansado M; Rubio-Terrés C
    Rev Esp Salud Publica; 2012 Dec; 86(6):601-12. PubMed ID: 23325135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement.
    Turun S; Banghua L; Yuan Y; Zhenhui L; Ying N; Jin C
    Thromb Res; 2011 Jun; 127(6):525-34. PubMed ID: 21397931
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Amniotic Mesenchymal Stromal Cells Exhibit Preferential Osteogenic and Chondrogenic Differentiation and Enhanced Matrix Production Compared With Adipose Mesenchymal Stromal Cells.
    Topoluk N; Hawkins R; Tokish J; Mercuri J
    Am J Sports Med; 2017 Sep; 45(11):2637-2646. PubMed ID: 28541092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
    Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
    N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.
    Bauersachs RM; Lensing AW; Prins MH; Kubitza D; Pap ÁF; Decousus H; Beyer-Westendorf J; Prandoni P
    Thromb J; 2014; 12():25. PubMed ID: 25750589
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of oral factor Xa inhibitor and low-molecular-weight heparin on surgical complications following total hip arthroplasty.
    Kim SM; Moon YW; Lim SJ; Kim DW; Park YS
    Thromb Haemost; 2016 Mar; 115(3):600-7. PubMed ID: 26790579
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.
    Cheung YW; Middeldorp S; Prins MH; Pap AF; Lensing AW; Ten Cate-Hoek AJ; Villalta S; Milan M; Beyer-Westendorf J; Verhamme P; Bauersachs RM; Prandoni P;
    Thromb Haemost; 2016 Sep; 116(4):733-8. PubMed ID: 27583311
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Osteoporosis and ageing affects the migration of stem cells and this is ameliorated by transfection with CXCR4.
    Sanghani-Kerai A; Coathup M; Samazideh S; Kalia P; Silvio LD; Idowu B; Blunn G
    Bone Joint Res; 2017 Jun; 6(6):358-365. PubMed ID: 28576885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study.
    Stepien K; Nowak K; Zalewski J; Pac A; Undas A
    Vascul Pharmacol; 2019 Sep; 120():106567. PubMed ID: 31158568
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PDGF receptor beta is a potent regulator of mesenchymal stromal cell function.
    Tokunaga A; Oya T; Ishii Y; Motomura H; Nakamura C; Ishizawa S; Fujimori T; Nabeshima Y; Umezawa A; Kanamori M; Kimura T; Sasahara M
    J Bone Miner Res; 2008 Sep; 23(9):1519-28. PubMed ID: 18410236
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
    Kakkar AK; Brenner B; Dahl OE; Eriksson BI; Mouret P; Muntz J; Soglian AG; Pap AF; Misselwitz F; Haas S;
    Lancet; 2008 Jul; 372(9632):31-9. PubMed ID: 18582928
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Insulin-Like Growth Factor-1 as a Possible Alternative to Bone Morphogenetic Protein-7 to Induce Osteogenic Differentiation of Human Mesenchymal Stem Cells in Vitro.
    Reible B; Schmidmaier G; Moghaddam A; Westhauser F
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29874864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sox11-modified mesenchymal stem cells (MSCs) accelerate bone fracture healing: Sox11 regulates differentiation and migration of MSCs.
    Xu L; Huang S; Hou Y; Liu Y; Ni M; Meng F; Wang K; Rui Y; Jiang X; Li G
    FASEB J; 2015 Apr; 29(4):1143-52. PubMed ID: 25466891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sub-confluent culture of human mesenchymal stromal cells on biodegradable polycaprolactone microcarriers enhances bone healing of rat calvarial defect.
    Lam AT; Sim EJ; Shekaran A; Li J; Teo KL; Goggi JL; Reuveny S; Birch WR; Oh SK
    Cytotherapy; 2019 Jun; 21(6):631-642. PubMed ID: 30975604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.